SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : A US National Health Care System? -- Ignore unavailable to you. Want to Upgrade?

To: Road Walker who wrote (2113)9/22/2007 4:31:10 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 42652
 
Economists say the slowdown has come about because more people are turning to generics and because generic versions of some of the most common drugs have recently come on the market.

I think this is only half the story. Please see the annotations in:
siliconinvestor.com

So should we shorten the time until generics are available?

The big issue now is biogenerics (or “biosimilar” drugs or “follow-on biologics”). It’s going to take a lot of negotiation to get a biogenerics bill through Congress—the last thing we need now is for someone to talk about changing the rules for generic small-molecule drugs. Regards, Dew



To: Road Walker who wrote (2113)9/23/2007 11:21:38 AM
From: TimF  Respond to of 42652
 
Maybe. Lower profit for the drug companies would reduce incentive for research and development, but probably not as much as direct or indirect price controls. Also reducing patents terms wouldn't be imposing some sort of command and control on the pharmaceutical market.

I'm not sure if I really want it to be shortened. But I would oppose any lengthening.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News